Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Ionis Pharmaceuticals Inc IONS
News
Ionis ranked #1 on Science’s Top Employers list
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — 2nd Update
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — Update
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
Ionis to present at upcoming investor conferences
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Major drugmaker loses $27 billion in market value after failed trial
United States